Pharmacoeconomics and Health Policy
- 1 January 1999
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 16 (5) , 425-432
- https://doi.org/10.2165/00019053-199916050-00001
Abstract
The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy decisions. Pharmacoeconomics is likely to become an increasingly important basis for health policy decisions as a number of significant dynamics evolve in the marketplace, including: (i) consumers acting on their growing access to information and becoming more actively involved in treatment decisions; (ii) payers, providers and patients deepening their interaction and overcoming their traditional (narrow) focus on either costs or benefits alone; and (iii) manufacturers being challenged by other healthcare constituencies as sponsors of cost-based outcomes studies.Keywords
This publication has 9 references indexed in Scilit:
- The Revised Canadian Guidelines for the Economic Evaluation of PharmaceuticalsPharmacoEconomics, 1999
- The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilizationStatistics in Medicine, 1998
- How to Calculate Indirect Costs in Economic EvaluationsPharmacoEconomics, 1998
- The Role of Cost-Effectiveness Analysis in Managed-Care DecisionsPharmacoEconomics, 1998
- Common Errors and Controversies in Pharmacoeconomic AnalysesPharmacoEconomics, 1998
- Pharmacoeconomics in the New MillenniumPharmacoEconomics, 1998
- Introduction and overviewSocial Science & Medicine, 1997
- The Societal Value of PharmaceuticalsPharmacoEconomics, 1996
- Foundations of Cost-Effectiveness Analysis for Health and Medical PracticesNew England Journal of Medicine, 1977